N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors
A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination With PD-(L)1 Monoclonal Antibody in Patients With Advanced Malignant Solid Tumors
Hefei Xinzhu Biological Technology Co., Ltd.
114 participants
Jun 15, 2026
INTERVENTIONAL
Conditions
Summary
This Phase I/II study evaluates the safety, tolerability, and efficacy of N-3C01 administered subcutaneously, both as monotherapy and in combination with a PD-(L)1 monoclonal antibody, in patients with advanced solid tumors. Phase I involves dose escalation for both monotherapy and combination therapy, while Phase II includes cohort expansion for the combination therapy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
subcutaneous injection once every 2 weeks
subcutaneous injection once every 3 weeks
subcutaneous injection once every 2 or 3 weeks.
intravenous injection once every 3 weeks
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07639450